Targeting the BCL-2 family in malignancies of germinal centre origin

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 12, 2009, Pages 1459-1472

  Spender, Lindsay C ^a   Inman, Gareth J ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

apoptosis; B cell; BCL 2 family; BH3 mimetics; Burkitt's lymphoma; germinal centre malignancy

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BCL2 RELATED PROTEIN A1; BIM PROTEIN; BORTEZOMIB; GLOBOTRIAOSYLCERAMIDE; IMMUNOGLOBULIN; KI 67 ANTIGEN; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; PROTEIN NOXA; PUMA PROTEIN; RITUXIMAB; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; B LYMPHOCYTE DIFFERENTIATION; BURKITT LYMPHOMA; CELL DEATH; CELL SURVIVAL; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; DRUG TARGETING; FOLLICULAR LYMPHOMA; GERMINAL CENTER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LYMPHATIC SYSTEM TUMOR; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MULTIPLE MYELOMA; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; B LYMPHOCYTE; DRUG EFFECT; GENETICS; NEOPLASM; PHYSIOLOGY; PROTO ONCOGENE;

ANIMALS; B-LYMPHOCYTES; GENES, BCL-2; GERMINAL CENTER; HUMANS; NEOPLASMS;

EID: 75349085052     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728220903379565     Document Type: Review

References (112)

1. MacLennan IC. Germinal centers. Annu Rev Immunol 1994;12117-39
2. Allen CD, Okada T, Tang HL, Cyster JG. Imaging of germinal center selection events during affinity maturation. Science 2007;315(5811):528-31 (Pubitemid 46175759)
3. Allen CD, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. Immunity 2007;27(2):190-202 (Pubitemid 47284923)
4. Berard M, Mondiere P, Casamayor-Palleja M, et al. Mitochondria connects the antigen receptor to effector caspases during B cell receptor-induced apoptosis in normal human B cells. J Immunol 1999;163(9):4655-62 (Pubitemid 29501225)
5. van Eijk M, Defrance T, Hennino A, de Groot C. Death-receptor contribution to the germinal-center reaction. Trends Immunol 2001;22(12):677-82 (Pubitemid 34008604)
6. Inman GJ, Allday MJ. Apoptosis induced by TGF-beta 1 in Burkitt's lymphoma cells is caspase 8 dependent but is death receptor independent. J Immunol 2000;165(5):2500-10 (Pubitemid 30660695)
7. Briere F, Defrance T, Vanbervliet B, et al. Transforming growth factor beta (TGF beta) directs IgA1 and IgA2 switching in human naive B cells. Adv Exp Med Biol 1995;371A21-6
8. Cazac BB, Roes J. TGF-beta receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 2000;13(4):443-51
9. Borsutzky S, Cazac BB, Roes J, Guzman CA. TGF-beta receptor signaling is critical for mucosal IgA responses. J Immunol 2004;173(5):3305-9 (Pubitemid 39142039)
10. Lebman DA, Edmiston JS. The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes. Microbes Infect 1999;1(15):1297-304 (Pubitemid 30020325)
11. Spender LC, O'Brien DI, Simpson D, et al. TGF-beta induces apoptosis in human B cells by transcriptional regulation of BIK and BCL-XL. Cell Death Differ 2009;16(4):593-602
12. Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood 2006;107(12):4589-96 (Pubitemid 43882602)
13. Kondo E, Yoshino T. Expression of apoptosis regulators in germinal centers and germinal center-derived B-cell lymphomas: insight into B-cell lymphomagenesis. Pathol Int 2007;57(7):391-7 (Pubitemid 46976406)
14. Lin B, Kolluri SK, Lin F, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004;116(4):527-40 (Pubitemid 38264430)
15. Kolluri SK, Zhu X, Zhou X, et al. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell 2008;14(4):285-98
16. Luciano F, Krajewska M, Ortiz-Rubio P, et al. Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma. Blood 2007;109(9):3849-55 (Pubitemid 46641736)
17. Takahashi Y, Cerasoli DM, Dal Porto JM, et al. Relaxed negative selection in germinal centers and impaired affinity maturation in bcl-xL transgenic mice. J Exp Med 1999;190(3):399-410
18. Tuscano JM, Druey KM, Riva A, et al. Bcl-x rather than Bcl-2 mediates CD40-dependent centrocyte survival in the germinal center. Blood 1996;88(4):1359-64 (Pubitemid 26276811)
19. Saltzman A, Munro R, Searfoss G, et al. Transforming growth factor-beta-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation. Exp Cell Res 1998;242(1):244-54 (Pubitemid 28366540)
20. Grillot DA, Merino R, Pena JC, et al. bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J Exp Med 1996;183(2):381-91
21. Zhang X, Li L, Choe J, et al. Up-regulation of Bcl-xL expression protects CD40-activated human B cells from Fas-mediated apoptosis. Cell Immunol 1996;173(1):149-54 (Pubitemid 26344931)
22. Nakayama K, Nakayama K, Negishi I, et al. Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. Science 1993;261(5128):1584-8 (Pubitemid 23319602)
23. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993;75(2):229-40 (Pubitemid 23320287)
24. Martinez-Valdez H, Guret C, de Bouteiller O, et al. Human germinal center B cells express the apoptosis-inducing genes Fas, c-myc, P53, and Bax but not the survival gene bcl-2. J Exp Med 1996;183(3):971-7
25. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 1991;349(6306):254-6 (Pubitemid 21912060)
26. Klein U, Tu Y, Stolovitzky GA, et al. Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci USA 2003;100(5):2639-44 (Pubitemid 36297551)
27. Caron G, Le Gallou S, Lamy T, et al. CXCR4 expression functionally discriminates centroblasts versus centrocytes within human germinal center B cells. J Immunol 2009;182(12):7595-602
28. Coultas L, Bouillet P, Stanley EG, et al. Proapoptotic BH3-only Bcl-2 family member Bik/Blk/Nbk is expressed in hemopoietic and endothelial cells but is redundant for their programmed death. Mol Cell Biol 2004;24(4):1570-81 (Pubitemid 38167079)
29. Craxton A, Chuang PI, Shu G, et al. The CD40-inducible Bcl-2 family member A1 protects B cells from antigen receptor-mediated apoptosis. Cell Immunol 2000;200(1):56-62 (Pubitemid 30170080)
30. Jiang A, Clark EA. Involvement of Bik, a proapoptotic member of the Bcl-2 family, in surface IgM-mediated B cell apoptosis. J Immunol 2001;166(10):6025-33 (Pubitemid 32440728)
31. O'Connor L, Strasser A, O'Reilly LA, et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. Embo J 1998;17(2):384-95 (Pubitemid 28045479)
32. Gomez-Bougie P, Bataille R, Amiot M. Endogenous association of Bim BH3-only protein with Mcl-1, Bcl-xL and Bcl-2 on mitochondria in human B cells. Eur J Immunol 2005;35(3):971-6 (Pubitemid 40425553)
33. Clybouw C, McHichi BE, Hadji A, et al. TGFbeta-mediated apoptosis of Burkitt's lymphoma BL41 cells is associated with the relocation of mitochondrial BimEL. Oncogene 2008;27(24):3446-56 (Pubitemid 351771305)
34. Enders A, Bouillet P, Puthalakath H, et al. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J Exp Med 2003;198(7):1119-26 (Pubitemid 37248627)
35. Goodyear CS, Corr M, Sugiyama F, et al. Cutting Edge: Bim is required for superantigen-mediated B cell death. J Immunol 2007;178(5):2636-40 (Pubitemid 46333137)
36. Fischer SF, Bouillet P, O'Donnell K, et al. Proapoptotic BH3-only protein Bim is essential for developmentally programmed death of germinal center-derived memory B cells and antibody-forming cells. Blood 2007;110(12):3978-84 (Pubitemid 350248453)
37. Erlacher M, Labi V, Manzl C, et al. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J Exp Med 2006;203(13):2939-51 (Pubitemid 46026171)
38. Hutcheson J, Scatizzi JC, Bickel E, et al. Combined loss of proapoptotic genes Bak or Bax with Bim synergizes to cause defects in hematopoiesis and in thymocyte apoptosis. J Exp Med 2005;201(12):1949-60 (Pubitemid 41002931)
39. Coultas L, Bouillet P, Loveland KL, et al. Concomitant loss of proapoptotic BH3-only Bcl-2 antagonists Bik and Bim arrests spermatogenesis. Embo J 2005 24(22):3963-73 (Pubitemid 41638002)
40. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 2009;16(3):368-77
41. Tabrizi SJ, Niiro H, Masui M, et al. T cell leukemia/lymphoma 1 and galectin-1 regulate survival/cell death pathways in human naive and IgM+ memory B cells through altering balances in Bcl-2 family proteins. J Immunol 2009;182(3):1490-9
42. Clybouw C, Hadji A, ElMchichi B, et al. BimL upregulation induced by BCR cross-linking in BL41 Burkitt's lymphoma results from a splicing mechanism of the BimEL mRNA. Biochem Biophys Res Commun 2009;383(1):32-6
43. Banerjee A, Grumont R, Gugasyan R, et al. NF-kB1 and c-Rel cooperate to promote the survival of TLR4-activated B cells by neutralizing Bim via distinct mechanisms. Blood 2008;112(13):5063-73
44. O'Reilly LA, Kruse EA, Puthalakath H, et al. MEK/ERK-mediated phosphorylation of Bim is required to ensure survival of T and B lymphocytes during mitogenic stimulation. J Immunol 2009;183(1):261-9
45. Stang SL, Lopez-Campistrous A, Song X, et al. A proapoptotic signaling pathway involving RasGRP, Erk, and Bim in B cells. Exp Hematol 2009;37(1):122-34
46. Richards S, Watanabe C, Santos L, et al. Regulation of B-cell entry into the cell cycle. Immunol Rev 2008;224183-200
47. Opferman JT, Letai A, Beard C, et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003;426(6967):671-6 (Pubitemid 38009376)
48. Woodland RT, Fox CJ, Schmidt MR, et al. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood 2008;111(2):750-60
49. Labi V, Erlacher M, Kiessling S, et al. Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates gamma irradiation-induced thymic lymphoma development. J Exp Med 2008;205(3):641-55 (Pubitemid 351439310)
50. Kuss AW, Knodel M, Berberich-Siebelt F, et al. A1 expression is stimulated by CD40 in B cells and rescues WEHI 231 cells from anti-IgM-induced cell death. Eur J Immunol 1999;29(10):3077-88 (Pubitemid 29484197)
51. Grumont RJ, Rourke IJ, Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev 1999;13(4):400-11 (Pubitemid 29108756)
52. Edelstein LC, Lagos L, Simmons M, et al. NF-kB-dependent assembly of an enhanceosome-like complex on the promoter region of apoptosis inhibitor Bfl-1/A1. Mol Cell Biol 2003;23(8):2749-61 (Pubitemid 36403075)
53. Pegman PM, Smith SM, D'Souza BN, et al. Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJk-dependent pathway. J Virol 2006;80(16):8133-44 (Pubitemid 44182313)
54. Yoon SO, Zhang X, Berner P, et al. Notch ligands expressed by follicular dendritic cells protect germinal center B cells from apoptosis. J Immunol 2009;183(1):352-8
55. Imaizumi K, Benito A, Kiryu-Seo S, et al. Critical role for DP5/Harakiri, a Bcl-2 homology domain 3-only Bcl-2 family member, in axotomy-induced neuronal cell death. J Neurosci 2004;24(15):3721-5 (Pubitemid 38509400)
56. Yin XM, Wang K, Gross A, et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999;400(6747):886-91 (Pubitemid 29406726)
57. Villunger A, Michalak EM, Coultas L, et al. p53-and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003;302(5647):1036-8 (Pubitemid 37386194)
58. Ranger AM, Zha J, Harada H, et al. Bad-deficient mice develop diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003;100(16):9324-9 (Pubitemid 37033927)
59. Garrison SP, Jeffers JR, Yang C, et al. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol 2008;28(17):5391-402
60. Michalak EM, Jansen ES, Happo L, et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ 2009;16(5):684-96
61. Erlacher M, Michalak EM, Kelly PN, et al. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation-and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 2005;106(13):4131-8 (Pubitemid 41775918)
62. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005;5(4):251-62 (Pubitemid 40488631)
63. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006;354(23):2431-42 (Pubitemid 43855046)
64. Efremov DG, Gobessi S, Longo PG. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. Autoimmun Rev 2007;7(2):102-8 (Pubitemid 350116720)
65. Monroe JG. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 2006;6(4):283-94
66. Gobessi S, Laurenti L, Longo PG, et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009;23(4):686-97
67. Habens F, Lapham AS, Dallman CL, et al. Distinct promoters mediate constitutive and inducible Bcl-XL expression in malignant lymphocytes. Oncogene 2007;26(13):1910-9 (Pubitemid 46474629)
68. Arena V, Martini M, Luongo M, et al. Mutations of the BIK gene in human peripheral B-cell lymphomas. Genes Chromosomes Cancer 2003;38(1):91-6 (Pubitemid 36994887)
69. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 2007;109(1):271-80 (Pubitemid 46053067)
70. Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005;436(7052):807-11 (Pubitemid 41160633)
71. Leonard JP, Gregory SA, Maloney DG, et al. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma. Clin Adv Hematol Oncol 2008;6(6):437-45
72. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26(25):3629-36 (Pubitemid 46842700)
73. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-kB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005;65(1):264-76 (Pubitemid 40070818)
74. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells. Blood 2002;100(1):194-9 (Pubitemid 35177447)
75. van de Donk NW, Kamphuis MM, van Dijk M, et al. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 2003;17(1):211-9 (Pubitemid 36175908)
76. Morales AA, Olsson A, Celsing F, et al. High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. Int J Cancer 2005;113(5):730-7 (Pubitemid 40101253)
77. Brien G, Trescol-Biemont MC, Bonnefoy-Berard N. Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene 2007;26(39):5828-32 (Pubitemid 47312815)
78. Olsson A, Norberg M, Okvist A, et al. Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia. Br J Cancer 2007;97(6):769-77 (Pubitemid 47396296)
79. Zhao WL, Daneshpouy ME, Mounier N, et al. Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood 2004;103(2):695-7 (Pubitemid 38140106)
80. Ghia P, Boussiotis VA, Schultze JL, et al. Unbalanced expression of Bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood 1998;91(1):244-51 (Pubitemid 28018751)
81. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008;7(12):989-1000
82. Azmi AS, Mohammad RM. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 2009;218(1):13-21
83. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009;15(4):1126-32
84. Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2008;112(5):1971-80
85. Perez-Galan P, Roue G, Lopez-Guerra M, et al. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia 2008;22(9):1712-20
86. Paoluzzi L, Gonen M, Gardner JR, et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 2008;111(11):5350-8
87. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10(5):389-99 (Pubitemid 44711953)
88. Labi V, Grespi F, Baumgartner F, Villunger A. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death Differ 2008;15(6):977-87 (Pubitemid 351712602)
89. Stolz C, Hess G, Hahnel PS, et al. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood 2008;112(8):3312-21
90. Whitecross KF, Alsop AE, Cluse LA, et al. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 2009;113(9):1982-91
91. Paoluzzi L, Gonen M, Bhagat G, et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008;112(7):2906-16
92. Kline MP, Rajkumar SV, Timm MM, et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 2007;21(7):1549-60 (Pubitemid 46965297)
93. Vogler M, Dinsdale D, Sun XM, et al. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 2008;15(5):820-30 (Pubitemid 351524424)
94. Jayanthan A, Howard SC, Trippett T, et al. Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma 2009;50(7):1174-82
95. Del Gaizo Moore V, Brown JR, Certo M, et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007;117(1):112-21 (Pubitemid 46048458)
96. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004;432(7017):635-9 (Pubitemid 39626271)
97. Kashatus D, Cogswell P, Baldwin AS. Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev 2006;20(2):225-35 (Pubitemid 43112940)
98. Hennino A, Berard M, Krammer PH, Defrance T. FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis. J Exp Med 2001;193(4):447-58 (Pubitemid 32524476)
99. van Eijk M, Medema JP, de Groot C. Cutting edge: cellular Fas-associated death domain-like IL-1-converting enzyme-inhibitory protein protects germinal center B cells from apoptosis during germinal center reactions. J Immunol 2001;166(11):6473-6 (Pubitemid 32467183)
100. Inman GJ, Nicolas FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002;62(1):65-74 (Pubitemid 34680517)
101. Yoshida T, Higuchi T, Hagiyama H, et al. Rapid B cell apoptosis induced by antigen receptorligationdoesnotrequireFas(CD95/APO-1), the adaptor protein FADD/MORT1 or CrmA-sensitive caspases but is defectiveinbothMRL-+/+ andMRL-lpr/lpr mice. Int Immunol 2000;12(4):517-26 (Pubitemid 30199357)
102. Ngan BY, Chen-Levy Z, Weiss LM, et al. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med 1988;318(25):1638-44
103. George NM, Evans JJ, Luo X. A three-helix homo-oligomerization domain containing BH3 and BH1 is responsible for the apoptotic activity of Bax. Genes Dev 2007;21(15):1937-48 (Pubitemid 47204932)
104. Letai A, Bassik MC, Walensky LD, et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002;2(3):183-92 (Pubitemid 41043974)
105. Kim H, Rafiuddin-Shah M, Tu HC, et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006;8(12):1348-58 (Pubitemid 44835109)
106. Gallenne T, Gautier F, Oliver L, et al. Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J Cell Biol 2009;185(2):279-90
107. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17(3):393-403 (Pubitemid 40193310)
108. Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006;9(5):351-65 (Pubitemid 43668734)
109. Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007;315(5813):856-9
110. Mittelstadt PR, DeFranco AL. Induction of early response genes by cross-linking membrane Ig on B lymphocytes. J Immunol 1993;150(11):4822-32 (Pubitemid 23150349)
111. Krajewski S, Bodrug S, Gascoyne R, et al. Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol 1994;145(3):515-25 (Pubitemid 24285958)
112. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998;91(9):3379-89 (Pubitemid 28193890)